| 中文名称 | 利福霉素钠 |
|---|---|
| 中文别名 | 利福霉素钠;力复霉素SV;利福霉素SV钠;(12Z,14E,24E)-(2S,16S,17S,18R,19R,20R,21S,22R,23S)-21-乙酰氧基-1,2-二氢-6,9,17,19-四羟基-23-甲氧基-2,4,12,16,18,20,22-七甲基-1,11-二氧-2,7-(十五碳环氧-1,11,13-三烯亚胺)苯并[2,1-b]呋喃-5-酚一钠盐;利福酶素 SV;利福霉素 SV;利福霉素 SV 钠盐;利福霉素S-NA盐;利福霉素S钠盐;利福霉素钠 EP标准品;利福霉素钠盐;对二甲氨基苯重氮磺酸钠;利福霉素纳;利福霉素钠,医药级,纯度:>99% |
| 英文名称 | Rifamycin sodium |
| 英文别名 | Rifamycin sodium salt;RIFAMPICIN SV SODIUM;RIFAMYCIN SV-SODIUM;RIFAMYCIN SV SODIUM SALT HEXAHYDRATE;Rifamycin SV Monosodium;RIFAMYCIN,MONOSODIUMSALT;Rifamycin SV hexahydrate sodium salt;RIFAMYCIN S SODIUM SALT;Rifamycin SV monosodium salt;Rifamycin SV Sodium;5,6,9,17,19,21-Hexahydroxy-23-Methoxy-2,4,12,16,18,20,22-heptaMethyl;monosodium rifamycin SV;Rifamycin sodium;Rifamycin SV sodium salt;2,7-(Epoxypentadeca[1,11,13]trienimino)naphtho[2,1-b]furan-1,11(2H)-dione,5,6,9,17,19,21-hexahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-,21-acetate, sodium salt (8CI);Rifamycin, monosodium salt (9CI);2,7-(Epoxypentadeca[1,11,13]trienimino)naphtho[2,1-b]furan, rifamycin deriv.;CB 01-11;NSC 146718;Tuborin;Rifamycin SV s;RifaMycin, sodiuM salt (1:1);RifamycinSV sodium salt;Rifamycin SV sodium, >=900 IU/mg;Sodium rifomycin SV;Rifamycin, monosodium salt;32086GS35Z;DSSTox_CID_20208;DSSTox_RID_79452;DSSTox_GSID_40208;Rifamycin sodium [USAN];Aemcolo;Otofa;RIFAMYCIN SV SODIUM SALT [MI];2,7-(EPOXYPENTADECA(1,11,13)TRIENIMINO)NAPHTHO(2,1-B)FURAN-1,11(2H)-DIONE, 5,6,9,17,19,21-HEXAHYDROXY-23-METHOXY-2,4,12,16,18,20,22-HEPTAMETHYL-, 21-ACETATE, SODIUM SALT;2,7-(Epoxypentadeca(1,11,13)trienimino)naphtho(2,1-b)furan-1,11(2H)-dione, 5,6,9,17,19,21-hexahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-, 21-acetate, monosodium salt;Rifamyzin-Natrium;SODIUM (2S,12Z,14E,16S,17S,18R,19R,20R,21S,22R,23S,24E)-21-(ACETYLOXY)-6,9,17,19-TETRAHYDROXY-23-METHOXY-2,4,12,16,18,20,22-HEPTAMETHYL-1,11-DIOXO-1,2-DIHYDRO-2,7-(EPOXYPENTADECA(1,11,13)TRIENIMINO)NAPHTHO(2,1-B)FURAN-5-OLATE;CB-0111;Rifamycin, sodium salt;2,7-(Epoxypentadeca(1,11,13)trienimino)naphtho(2,1-b)furan-1,11(2H)-dione, 5,6,9,17,19,21-hexahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-, 21-acetate, sodium;J-008536;RIFAMYCIN SODIUM [MART.];NSC 133100;SODIUM (2S,12Z,14E,16S,17S,18R,19R,20R,21S,22R,23S,24E)-21-(ACETYLOXY)- 6,9,17,19-TETRAHYDROXY-23-METHOXY-2,4,12,16,18,20,22-HEPTAMETHYL-1,11-DIOXO-1,2- DIHYDRO-2,7-(EPOXYPENTADECA(1,11,13)TRIENIMINO)NAPHTHO(2,1-B)FURAN-5-OLATE;Rifamycinum natricum;Rifamycin SV sodium salt, potency: >=900 units (dry basis);Rifamycin SV;DTXSID0040208;sodium;(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-13-acetyloxy-2,15,17,29-tetrahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-27-olate;RIFAMYCIN SODIUM (MART.);14897-39-3;RIFAMYCIN SODIUM [WHO-DD];Q27256110;UNII-32086GS35Z;CB-01-11;RIFAMYCIN SODIUM (EP IMPURITY);RIFAMYCIN SODIUM (EP MONOGRAPH);RIFAMYCIN SODIUM [EP IMPURITY];RIFAMYCIN SODIUM [ORANGE BOOK];CB-01-11, Rifamycin SV;Rifamastene;EINECS 238-965-7;RIFAMYCIN SODIUM [EP MONOGRAPH] |
| CAS No. | 14897-39-3 |
| 分子式 | C37H46NNaO12 |
| 分子量 | 719.75 |
4-(2-((2R,3R)-3-(2,5-二氟苯基)-3-羟基-4-(1H-1,2,4-三唑-1-基)丁-2-基)噻唑-4-基)苯甲腈
N-(丁基磺酰基)-O-[4-(4-哌啶基)丁基]-L-酪氨酸盐酸盐一水合物
2-(4-(1-羟基-4-(4-(羟基二苯基甲基)哌啶-1-基)丁基)苯基)-2-甲基丙酸
7-环戊基-N,N-二甲基-2-((5-(哌嗪-1-基)吡啶-2-基)氨基)-7H-吡咯并[2,3-d]嘧啶-6-甲酰胺
(1-((2R,3R,4S,5R)-3,4-二羟基-5-甲基四氢呋喃-2-基)-5-氟-2-氧代-1,2-二氢嘧啶-4-基)氨基甲酸戊酯
((3S,5R)-5-((1H-1,2,4-三唑-1-基)甲基)-5-(2,4-二氟苯基)四氢呋喃-3-基)甲基 4-甲基苯磺酸酯
N-(3-氯-4-氟苯基)-7-甲氧基-6-(3-吗啉-4-丙氧基)喹唑啉-4-胺
(6R,7R)-3-甲基-7-[(R)-2-氨基-2-苯乙酰氨基]-8-氧-5-硫杂-1-双环[4.2.0]辛-2-烯-2-甲酸
(2R,3S,5S)-3-苄氧基-5-[2-[[(4-甲氧基苯基)二苯基甲基]氨基]-6-苄氧基-9H-嘌呤-9-基]-2-苄氧基甲基环戊醇
(2R,3R,4S,5R)-2-(4-氨基吡咯并[2,1-F][1,2,4]三嗪-7-基)-3,4-二羟基-5-(羟甲基)四氢呋喃-2-甲腈
本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用。
CopyRight @2025 广东元丰化学试剂有限公司 版权所有 | 隐私政策 条款及条件 | 粤ICP备2025403430号-1
技术支持:库价化学